📊 RARE Key Takeaways
Is Ultragenyx Pharmaceutical Inc. (RARE) a Good Investment?
Ultragenyx faces severe fundamental challenges including negative stockholders' equity of -$80M, unsustainable free cash flow burn of -$472M annually, and deeply unprofitable operations at -85.4% net margin despite 20.2% revenue growth. While the company maintains adequate short-term liquidity with $421M cash, this covers less than one year of current cash burn, creating material solvency risk without significant operational improvements or capital infusion.
Why Buy Ultragenyx Pharmaceutical Inc. Stock? RARE Key Strengths
- Revenue growth of 20.2% YoY demonstrates market demand for product portfolio
- Adequate current liquidity ratio of 2.48x provides near-term operational flexibility
- Cash position of $421M provides runway to reach potential profitability milestones
RARE Stock Risks: Ultragenyx Pharmaceutical Inc. Investment Risks
- Negative stockholders' equity of -$80M indicates balance sheet insolvency and elevated bankruptcy risk
- Free cash flow burn of -$472M annually far exceeds cash runway of approximately 11 months
- Operating losses of -$535M on $673M revenue suggest unsustainable business model economics and likely continued cash depletion
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Cash runway depletion rate and timing to next capital requirement
- Product pipeline advancement and near-term commercialization catalysts for revenue acceleration
Ultragenyx Pharmaceutical Inc. (RARE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.48x current ratio provides a solid financial cushion.
RARE Profit Margin, ROE & Profitability Analysis
RARE vs Healthcare Sector: How Ultragenyx Pharmaceutical Inc. Compares
How Ultragenyx Pharmaceutical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ultragenyx Pharmaceutical Inc. Stock Overvalued? RARE Valuation Analysis 2026
Based on fundamental analysis, Ultragenyx Pharmaceutical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ultragenyx Pharmaceutical Inc. Balance Sheet: RARE Debt, Cash & Liquidity
RARE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ultragenyx Pharmaceutical Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.25 indicates the company is currently unprofitable.
RARE Revenue Growth, EPS Growth & YoY Performance
RARE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $139.5M | -$133.5M | $-1.40 |
| Q2 2025 | $147.0M | -$115.0M | $-1.17 |
| Q1 2025 | $108.8M | -$151.1M | $-1.57 |
| Q3 2024 | $98.1M | -$133.5M | $-1.40 |
| Q2 2024 | $108.3M | -$131.6M | $-1.52 |
| Q1 2024 | $100.5M | -$164.0M | $-2.03 |
| Q3 2023 | $90.7M | -$159.6M | $-2.23 |
| Q2 2023 | $89.3M | -$158.2M | $-2.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ultragenyx Pharmaceutical Inc. Dividends, Buybacks & Capital Allocation
RARE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ultragenyx Pharmaceutical Inc. (CIK: 0001515673)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RARE
What is the AI rating for RARE?
Ultragenyx Pharmaceutical Inc. (RARE) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RARE's key strengths?
Claude: Revenue growth of 20.2% YoY demonstrates market demand for product portfolio. Adequate current liquidity ratio of 2.48x provides near-term operational flexibility.
What are the risks of investing in RARE?
Claude: Negative stockholders' equity of -$80M indicates balance sheet insolvency and elevated bankruptcy risk. Free cash flow burn of -$472M annually far exceeds cash runway of approximately 11 months.
What is RARE's revenue and growth?
Ultragenyx Pharmaceutical Inc. reported revenue of $673.0M.
Does RARE pay dividends?
Ultragenyx Pharmaceutical Inc. pays dividends, with $4.3M distributed to shareholders in the trailing twelve months.
Where can I find RARE SEC filings?
Official SEC filings for Ultragenyx Pharmaceutical Inc. (CIK: 0001515673) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RARE's EPS?
Ultragenyx Pharmaceutical Inc. has a diluted EPS of $-5.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RARE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ultragenyx Pharmaceutical Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RARE stock overvalued or undervalued?
Valuation metrics for RARE: ROE of N/A (sector avg: 15%), net margin of -85.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RARE stock in 2026?
Our dual AI analysis gives Ultragenyx Pharmaceutical Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RARE's free cash flow?
Ultragenyx Pharmaceutical Inc.'s operating cash flow is $-466.0M, with capital expenditures of $6.0M. FCF margin is -70.1%.
How does RARE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -85.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.48 (avg: 2).